45 related articles for article (PubMed ID: 28960427)
1. Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL).
Tandon N; Sidana S; Dispenzieri A; Gertz MA; Lacy MQ; Dingli D; Buadi FK; Fonder AL; Hayman SR; Hwa YL; Hobbs MA; Kapoor P; Gonsalves WI; Leung N; Go RS; Lust JA; Russell SJ; Kyle RA; Rajkumar SV; Kumar SK
Am J Hematol; 2018 Jan; 93(1):17-22. PubMed ID: 28960427
[TBL] [Abstract][Full Text] [Related]
2. Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosis.
Bomsztyk J; Ravichandran S; Giles HV; Wright N; Berlanga O; Khwaja J; Mahmood S; Wisniowski B; Cohen O; Foard D; Gilbertson J; Rauf MU; Starr N; Martinez-Naharro A; Venneri L; Whelan C; Fontana M; Hawkins PN; Gillmore JD; Lachmann H; Harding S; Pratt G; Wechalekar AD
Blood; 2024 Mar; 143(13):1259-1268. PubMed ID: 38194690
[TBL] [Abstract][Full Text] [Related]
3. Outcomes for patients with systemic light chain amyloidosis and Mayo stage 3B disease.
Theodorakakou F; Briasoulis A; Fotiou D; Petropoulos I; Georgiopoulos G; Lama N; Kelekis N; Repasos E; Migkou M; Stamatelopoulos K; Dimopoulos MA; Kastritis E
Hematol Oncol; 2023 Oct; 41(4):725-732. PubMed ID: 36974438
[TBL] [Abstract][Full Text] [Related]
4. Serum monoclonal immunoglobulin light-chain detection differs between immunofixation electrophoresis methods in patients with AL amyloidosis.
Kawano Y; Nishimura N; Yasunaga JI
Int J Hematol; 2024 May; ():. PubMed ID: 38739302
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis.
Cohen OC; Ismael A; Pawarova B; Manwani R; Ravichandran S; Law S; Foard D; Petrie A; Ward S; Douglas B; Martinez-Naharro A; Chacko L; Quarta CC; Mahmood S; Sachchithanantham S; Lachmann HJ; Hawkins PN; Gillmore JD; Fontana M; Falk RH; Whelan CJ; Wechalekar AD
Eur Heart J; 2022 Jan; 43(4):333-341. PubMed ID: 34472567
[TBL] [Abstract][Full Text] [Related]
6. Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib.
Ravichandran S; Cohen OC; Law S; Foard D; Fontana M; Martinez-Naharro A; Whelan C; Gillmore JD; Lachmann HJ; Sachchithanantham S; Mahmood S; Hawkins PN; Wechalekar AD
Blood Cancer J; 2021 Jun; 11(6):118. PubMed ID: 34155191
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of Holter Monitoring in Light Chain Amyloidosis.
Sun Y; Zhao Q; Liu Y; Wen L; Dou X; Lu J; Liu J
J Clin Med; 2023 Dec; 12(23):. PubMed ID: 38068514
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of Modified Mayo Stage IIIa and IIIb Cardiac Light-Chain Amyloidosis: Real-World Experience in Clinical Characteristics and Treatment-67 Patients Multicenter Analysis.
Charliński G; Steinhardt M; Rasche L; Gonzalez-Calle V; Peña C; Parmar H; Wiśniewska-Piąty K; Dávila Valls J; Olszewska-Szopa M; Usnarska-Zubkiewicz L; Gozzetti A; Ciofini S; Gentile M; Zamagni E; Kurlapski M; Legieć W; Vesole DH; Jurczyszyn A
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672674
[TBL] [Abstract][Full Text] [Related]
9. Localized immunoglobulin light chain amyloidosis: Novel insights including prognostic factors for local progression.
Basset M; Hummedah K; Kimmich C; Veelken K; Dittrich T; Brandelik S; Kreuter M; Hassel J; Bosch N; Stuhlmann-Laeisz C; Blank N; Müller-Tidow C; Röcken C; Hegenbart U; Schönland S
Am J Hematol; 2020 Oct; 95(10):1158-1169. PubMed ID: 32602121
[TBL] [Abstract][Full Text] [Related]
10. Using a Modified Delphi Panel to Estimate Health Service Utilization for Patients with Advanced and Non-Advanced Systemic Light Chain Amyloidosis.
Gertz M; Abonour R; Gibbs SN; Finkel M; Landau H; Lentzsch S; Lin G; Mahindra A; Quock T; Rosenbaum C; Rosenzweig M; Sidana S; Tuchman SA; Witteles R; Yermilov I; Broder MS
Clinicoecon Outcomes Res; 2023; 15():673-680. PubMed ID: 37719133
[TBL] [Abstract][Full Text] [Related]
11. Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation.
Sidiqi MH; Aljama MA; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Leung N; Gonsalves WI; Kumar SK; Kapoor P; Kourelis TV; Hogan WJ; Gertz MA
Blood Adv; 2018 Apr; 2(7):769-776. PubMed ID: 29615413
[TBL] [Abstract][Full Text] [Related]
12. AL amyloidosis: from molecular mechanisms to targeted therapies.
Merlini G
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):1-12. PubMed ID: 29222231
[TBL] [Abstract][Full Text] [Related]
13. Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.
Chim CS; Kumar SK; Orlowski RZ; Cook G; Richardson PG; Gertz MA; Giralt S; Mateos MV; Leleu X; Anderson KC
Leukemia; 2018 Feb; 32(2):252-262. PubMed ID: 29257139
[TBL] [Abstract][Full Text] [Related]
14. Right ventricular longitudinal strain: a tool for diagnosis and prognosis in light-chain amyloidosis.
Uzan C; Lairez O; Raud-Raynier P; Garcia R; Degand B; Christiaens LP; Rehman MB
Amyloid; 2018 Mar; 25(1):18-25. PubMed ID: 29260587
[TBL] [Abstract][Full Text] [Related]
15. Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis.
Kastritis E; Fotiou D; Theodorakakou F; Dialoupi I; Migkou M; Roussou M; Karatrasoglou EA; Tselegkidi MI; Ntalianis A; Kanellias N; Eleutherakis-Papaiakovou E; Ntanasis-Stathopoulos I; Gakiopoulou C; Papanikolaou A; Papathoma A; Spyropoulou-Vlachou M; Psimenou E; Stamatelopoulos K; Gavriatopoulou M; Terpos E; Dimopoulos MA
Amyloid; 2021 Mar; 28(1):3-11. PubMed ID: 32713209
[TBL] [Abstract][Full Text] [Related]
16. Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio.
Muchtar E; Gertz MA; Lacy MQ; Leung N; Buadi FK; Dingli D; Hayman SR; Go RS; Kapoor P; Gonsalves W; Kourelis TV; Warsame R; Hwa YL; Fonder A; Hobbs M; Russell S; Lust JA; Siddiqui M; Rajkumar SV; Kyle RA; Kumar SK; Dispenzieri A
Am J Hematol; 2020 Nov; 95(11):1280-1287. PubMed ID: 32681737
[TBL] [Abstract][Full Text] [Related]
17. RECIL versus Lugano for Treatment Response Assessment in FDG-Avid Non-Hodgkin Lymphomas: A Head-to-Head Comparison in 54 Patients.
Berzaczy D; Haug A; Staber PB; Raderer M; Kiesewetter B; Jaeger U; Kornauth C; Simonitsch-Klupp I; Mayerhoefer ME
Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31861433
[TBL] [Abstract][Full Text] [Related]
18. Revisiting complete response in light chain amyloidosis.
Sidana S; Dispenzieri A; Murray DL; Go RS; Buadi FK; Lacy MQ; Gonsalves WI; Dingli D; Warsame R; Kourelis T; Muchtar E; Hayman SR; Kapoor P; Kyle RA; Leung N; Rajkumar SV; Gertz MA; Kumar SK
Leukemia; 2020 May; 34(5):1472-1475. PubMed ID: 31772296
[No Abstract] [Full Text] [Related]
19. The Amyloidosis Forum: a public private partnership to advance drug development in AL amyloidosis.
; Lousada I
Orphanet J Rare Dis; 2020 Sep; 15(1):268. PubMed ID: 32993758
[TBL] [Abstract][Full Text] [Related]
20. Advances in the Treatment of Cardiac Amyloidosis.
Macedo AVS; Schwartzmann PV; de Gusmão BM; Melo MDT; Coelho-Filho OR
Curr Treat Options Oncol; 2020 Apr; 21(5):36. PubMed ID: 32328845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
